Clinical Trial

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2024 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06490081
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Myelosuppression
Enrollment 40 participants
Start Date 2024-06-26
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-24